Roche reports promising results from anti-Covid cocktail

The results of the Phase 3 trial showed that the combination of the antibodies casirivimab and imdevimab "reduced hospitalisation or death by 70 percent in non-hospitalised patients with COVID-19," it said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3f8IIiz
via IFTTT